Peer-Reviewed Publications

      Preliminary toxicological assessment of heated tobacco products: A review of the literature and proposed strategy

      Dempsey, R.; Rodrigo, G.; Vonmoos, F.; Gunduz, I.; Belushkin, M.; Esposito, M.

      Published
      Jan 20, 2023
      DOI
      10.1016/j.toxrep.2023.01.008
      Link to publication
      Topic
      Summary

      Heated tobacco products (HTPs) have become increasingly common in many countries worldwide. The principle of heating tobacco, without combustion, to produce a nicotine-containing aerosol with remarkably reduced levels of other known toxins, compared to combusted tobacco cigarettes, is now well established. As these products are intended as alternatives to traditional combusted products, during the early stages of their development, it is important for manufacturers to ensure that the design of the product does not lead to any unintentionally increased or new risk for the consumer, compared to the traditional products that consumers seek to replace. There is limited guidance from tobacco product regulations concerning the requirements for performing such preliminary toxicological assessments. Here, we review the published literature on studies performed on HTPs in the pursuit of such data, outline a proposed approach that is consistent with regulatory requirements, and provide a logical approach to the preliminary toxicological assessment of HTPs.

      Related Publications

      Fourier Transformed Infrared (FTIR) Method For Continuous Real-Time Aerosol Characterization For In Vivo Studies

      Aerosol Chemistry Pre-clinical Toxicology

      Chemical Composition, In Vitro Toxicity, and Theoretical Risk Estimates of Smoke from Different U.S. Blended Cigarettes

      Aerosol Chemistry Pre-clinical Toxicology

      A novel method for multi-component continuous real-time aerosol monitoring using Fourier Transformed Infrared (FTIR) spectroscopy for in vivo studies

      Aerosol Chemistry Pre-clinical Toxicology

      Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 2: Smoke chemistry and in vitro toxicological evaluation using smoking regimens reflecting human puffing behavior

      Aerosol Chemistry Pre-clinical Toxicology

      Evaluation of the potential effects of ingredients added to cigarettes. Part 1: Cigarette design, testing approach, and review of results

      Aerosol Chemistry Pre-clinical Toxicology

      Mainstream smoke chemistry and in vitro and in vivo toxicity of the reference cigarettes 3R4F and 2R4F

      Aerosol Chemistry Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.